Biogen is entitled to damages in Tecfidera case rules Regional Court Hamburg

The Hamburg Regional Court has ruled that Biogen is entitled to damages from several generics companies, including Viatris, Hexal, Neuraxpharm, and Zentiva, for selling their dimethyl fumarate generics before the market exclusivity for Tecfidera ended. Biogen asserts that its market exclusivity ran until February 2024, claiming hundreds of millions in damages due to lost sales. The court’s decision establishes Biogen’s entitlement to damages, with the specific amount yet to be determined, noting the generics companies acted at least negligently despite legal uncertainties.